deltatrials
Completed PHASE4 INTERVENTIONAL NCT00165724

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Sponsor: Eisai Korea Inc.

Updated 7 times since 2017 Last updated: Dec 10, 2021 Started: Jun 30, 2004 Primary completion: Jul 31, 2006 Completion: Dec 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Alzheimer's Disease, this trial is completed. The trial is conducted by Eisai Korea Inc. and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotCompleted~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE4

Show 2 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Korea Inc.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .